Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
RARRES2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of RARRES2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRU Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRU sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRS Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRS sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRO Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRO sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRF Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTH1R Biologics Sequence Review Report 2026: Parathyroid hormone/parathyroid hormone-related peptide receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTH1R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PRTN3 Biologics Sequence Review Report 2026: Myeloblastin Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PRTN3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PROS1 Biologics Sequence Review Report 2026: Vitamin K-dependent protein S Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PROS1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PROKR2 Biologics Sequence Review Report 2026: Prokineticin receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PROKR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PROKR1 Biologics Sequence Review Report 2026: Prokineticin receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PROKR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PROCR Biologics Sequence Review Report 2026: Endothelial protein C receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PROCR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.